The faecal immunochemical test (FIT) is one of the tests recommended by different societies for colorectal cancer (CRC) screening in average-risk populations ([@bib7]). Faecal immunochemical test is performed annually or biennially after age 50. In a recently published population-based, randomised trial, FIT detected an equivalent number of CRC as colonoscopy in the first CRC screening round ([@bib9]).

There is no consensus among experts about whether oral anticoagulants (OACs) alone or in combination with antiplatelet drugs should be suspended before stool collection for FIT ([@bib6]; [@bib10]; [@bib8]). Previous studies from our group have observed aspirin and antiplatelets should not be stopped before FIT, as these drugs do not diminish the positive predictive value (PPV) for advanced neoplasia (AN; [@bib2]).

The objective of this study was to determine whether the use of OAC, alone or in combination with antiplatelet drugs, affects the positivity and detection rates for AN in average-risk subjects undergoing CRC screening.

Materials and methods
=====================

Study design
------------

We performed a *post hoc* analysis of subjects assigned to the FIT arm of the COLONPREV trial, a randomised controlled study aimed at comparing one-time colonoscopy *vs* biennial FIT for the reduction of CRC-related mortality at 10 years in an average-risk population. The study, described in detail elsewhere ([@bib9]), started in November 2008 and the first round was completed in June 2011. Subjects agreeing to participate in the study received an appointment to the local screening office. The data manager conducted a questionnaire (face to face) about taking drugs (type, dose and frequency). Patients usually have a list of the drugs they take. At the time of the interview, data manager explained how to make the FIT without stopping any medication.

Faecal immunochemical test strategy consisted of a single sample using the automated semiquantitative OC-Sensor kit (Eiken Chemical Co., Tokyo, Japan), without any specific diet or medication limitations. Patients with ⩾75 ng haemoglobin per ml of buffer solution (⩾15 μg of haemoglobin per gram of faeces) were invited for a colonoscopy ([@bib4]).

Within this cohort, we defined the 'users\' as those reporting chronic use of OAC (acenocoumarol), alone or in combination with antiplatelet drugs. Antiplatelet drugs were aspirin ⩽300 mg day^--1^ or clopidogrel. The non-users group consisted of subjects not taking any of these drugs, either chronically or sporadically, within 30 days of testing. Patients taking these drugs intermittently or sporadically within 30 days of testing were excluded from the analysis. Individuals taking new anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) or non-steroidal anti-inflammatory drugs were also excluded. No change in medication before stool collection was recommended.

Adenomas ⩾10 mm in size, with villous architecture, high-grade dysplasia or intramucosal carcinoma were classified as advanced adenomas. Advanced neoplasia was defined as advanced adenoma or invasive cancer. Non-AN (NAN) were classified as the presence of one or two small adenomas \<10 mm. Invasive cancer was considered to exist when malignant cells were observed beyond the *muscularis mucosa*. A specific program was designed to ensure the quality of the whole process ([@bib5]; [@bib9]).

Statistical analysis
--------------------

Chi-square test and/or Fisher test was used to compare categorical variables across the groups and one-way ANOVA was used to compare continuous variables. Faecal haemoglobin measurements are presented as medians and compared using the non-parametric Kruskal--Wallis test. The positivity rate and the PPV was calculated for the users and non-users group.

Results
=======

Postal invitations to undergo FIT were sent to a total of 28 696 individuals, with a mean age of 59.5±5.5 years, 47% were men. Of them 1054 (3.6%) invitations were returned unanswered. In addition, 1043 (3.6%) were excluded either permanently or temporarily. The eligible population consisted of 26 599 people.

A total of 10 611 (36.9%) individuals returned the test and 6045 (56.9%) fulfilled the questionnaire and reported adequate information on the use of OAC ([Figure 1](#fig1){ref-type="fig"}). Mean age was 59.5±5.6 years and 2803 (46%) were men. Of the 6045 participants, 5821 (96.3%) reported not using any of these drugs (non-users group), and 224 (3.7%) reported taking OAC alone or in combination with antiplatelet drugs before testing (users group). In the users group, 164 individuals reported taking OAC alone and 60 OAC in combination with antiplatelet drugs. As expected, more men were taking these drugs than women and age was higher in those taking antiplatelet drugs than in non-users ([Table 1](#tbl1){ref-type="table"}). There were no differences in the type or the location of lesions (CRC, AN and NAN) between users and non-users group.

Faecal immunochemical test was positive for occult blood in 386 of 6045 participants (6.3%). Of the 386 people with positive test, colonoscopy was normal in 124 (32%) cases, whereas 20 (5%) had CRC, 174 (45%) AA and 68 (18%) NAN. Tumour staging of identified lesions (FIT: stage I in 16; stage II in 2 and stage III in 2).

Faecal immunochemical test was positive in (21 out of 224) 9.3% of the users group and (365 out of 5821) 6.2% in the non-users group (*P*-trend=0.07; [Table 2](#tbl2){ref-type="table"}). The number of AN found in the OAC more antiplatelet therapy users not differ significantly with non-users ([Table 3](#tbl3){ref-type="table"}). The PPV for AN in OAC more antiplatelets (aspirin or clopidogrel) was 75% (odds ratio, 2; 95% CI, 0.4--10.8; *P*=0.4). Median haemoglobin concentration detected in the stool did not differ significantly between non-users and users (285 ng ml^--1^ *vs* 502 ng ml^--1^; *P*-trend=0.2).

The PPV for AN in the non-user group was 50.4% and 47.6% ([Table 4](#tbl4){ref-type="table"}). The PPV for NAN was 50.4% (184 out of 365), 30.8% (4 out of 13) and 75% (6 out of 8), in the non-users, OAC, and OAC in combination with other drugs respectively, without significant differences (*P*=0.2).

Discussion
==========

The number of people with long-term OAC therapy is increasing. In 2006, 4% of the population taking OAC (equal to our study) and 9% of those over 65 years ([@bib3]). Patients with prosthetic heart valves, chronic or paroxysmal atrial fibrillation, recurrent deep venous thrombosis, hypercoagulable diseases, and vascular diseases are currently maintained on long-term anticoagulants. Anticoagulation is mandatory to reduce the risk of thromboembolism, but at the same time the therapy increases the risk of bleeding.

In our study, the OAC alone or in combination with antiplatelet drugs showed increased FIT positivity without increasing the false positivity rate. The rate of positive for control, OAC and the combination were 6.2%, 7.9% and 13.3%, respectively. There were no statistically significant differences in the PPV for AN in comparing with non-users. Only three studies ([@bib6]; [@bib10]; [@bib8]) have analysed the effect of OAC on the FIT performance. A study ([@bib6]) includes 16 individuals taking warfarin, nevertheless, concluded that anticoagulants were associated increased sensitivity with no change in specificity for NA. Another study ([@bib8]) examines 53 patients taking OAC with positive FIT and compared with 106 controls (positive FIT without OAC). Advanced neoplasia was detected in 28.3% of cases and 34.9% of controls without statistically significant difference. The third study ([@bib10]) concluded that OAC reduces the PPV for AN compared with controls (20% in OAC *vs* 30% in controls). However, this study has some differences with our research, the number of patients taking anticoagulants was lower (85 individuals), the test used was the haemoccult II and patients were not a screening program. In the latter study, the percentage of patients with CRC and AN was low, 3.1% and 24%, respectively, probably due to the test performed. In our study, the proportion of CRC and AN in patients with positive FIT was 5% and 50%, respectively. Our data suggest that combination therapy increases bleeding of AN facilitating their detection with FIT. Another advantage by not suspending the anticoagulant is that it can also help increase public participation in CRC screening since discontinuation has been linked to increased risk of stroke and other adverse cardiovascular events ([@bib1]).

This study has certain strengths. First, its database was that of a prospective clinical trial without selection bias, which should minimise confounders for the detection of AA and AN. Second, the number of cases analysed is higher than that reported to date ([@bib6]; [@bib10]; [@bib8]. Third, the original trial was performed with FIT, unlike others which have used the guaiac faecal occult blood test ([@bib10]). Finally, the study was performed in asymptomatic individuals, in contrast to other studies ([@bib6]; [@bib10]).

The study also has some limitations. First, colonoscopy was not performed on patients with a negative FIT, so we were not able to determine the influence OAC drugs may have had on the negative predictive value of FIT. Second, no information was collected on prothrombin time-international normalised ratio at the time of the FIT. Third, other factors such as history of gastrointestinal bleeding or presence of serious comorbid conditions (acute myocardial infraction, renal insufficiency and severe anaemia), can interfere results. Finally, the number of patients in the combined group (OAC more antiplatelets) with positive FIT and AN were low.

In conclusion, we found that the anticoagulants alone or in combination with antiplatelet drugs did not reduce the PPV of FIT for AN. This suggests that OAC therapy should not be discontinued before stool collection for FIT.
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###### 

Click here for additional data file.

![**Study recruitment and participant flow.**](bjc201438f1){#fig1}

###### Characteristics of individuals included in the study

                               **Users group (*n*=224)**   **Non-users group (*n*=5821)**   ***P*-value**
  ---------------------------- --------------------------- -------------------------------- ---------------
  Positive FIT                 21 (9.3%)                   365 (6.2%)                       0.07
  Age (years-old)              62.2 (s.d.: 5.6)            59.4 (s.d.: 5.5)                 \<0.001
  Male sex (%)                 140 (54.1%)                 2663 (46%)                       0.003
  Proton pump inhibitor        134 (60%)                   874 (15%)                        \<0.001
  **Cardiac disease**                                                                       
  Valve prosthesis             28 (12.5%)                  ---                               
  Atrial fibrillation          140 (62.5%)                 128 (2.2%)                       \<0.001
  Prevention thromboembolism   42 (18.75%)                 ---                               
  Others                       14 (6.5%)                   ---                               
  Ischemic stroke-heart        67 (30%)                    320 (5.5%)                       \<0.001
  **Results of colonoscopy**                                                                
  Cancer                       1 (4.8%)                    19 (5.2%)                        0.5
  Advanced adenoma             9 (42.9%)                   165 (45.2%)                       
  Non-advanced adenoma         4 (19%)                     64 (17.5%)                        
  Normal                       7 (33.3%)                   117 (32.1%)                       
  **Location of lesions**                                                                   
  Distal                       10 (71.5%)                  180 (72.6%)                      0.5
  Proximal                     4 (28.5%)                   68 (27.4%)                        

Abbreviation: FIT=faecal immunochemical test.

###### Comparison of FIT-positive rate between OACs non-user and user groups

                    **Individuals**   **+FIT**, **no. (%)**    **OR**[a](#t2-fn2){ref-type="fn"}   **95% CI**  ***P*-value**[b](#t2-fn3){ref-type="fn"}
  ----------------- ----------------- ----------------------- ----------------------------------- ------------ ------------------------------------------
  Non-users group   5821              365 (6.2)                            1 (Ref.)                             
  Users group       224               21 (9.3)                                1.3                   0.8--2.1   0.3
   OAC              164               13 (7.9)                               1.15                   0.6--2.1   0.6
   OAC+others       60                8 (13.3)                                1.8                   0.8--3.9   0.2

Abbreviations: CI=confidence interval; FIT=faecal immunochemical test; OAC=oral anticoagulant; OR=odds ratio; Others=aspirin ⩽300 mg day^--1^ or clopidogrel.

OR, comparing users with non-users, adjusted for age and sex.

Compared with non-users.

###### AN found in each group

                    **Individuals**   **AN**, **no. (%)**    **OR**[a](#t3-fn3){ref-type="fn"}  **95% CI**   ***P-*value**[b](#t3-fn3){ref-type="fn"}
  ----------------- ----------------- --------------------- ----------------------------------- ------------ ------------------------------------------
  Non-users group   5821              184 (3.2)                          1 (Ref.)                             
  Users group       224               10 (4.5)                              1.1                 0.5--2.1     0.8
   OAC              164               4 (2.4)                               0.6                 0.2--1.7     0.4
   OAC+others       60                6 (10)                                2.3                 0.9--5.9     0.08

Abbreviations: AN=advanced neoplasm; CI=confidence interval; FIT=faecal immunochemical test; OAC=oral anticoagulant; OR=odds ratio; Others=aspirin ⩽300 mg day^--1^ or clopidogrel.

OR, comparing users with non-users, adjusted for age and sex.

Compared with non-users.

###### Positive predictive value of faecal immunochemical test for AN according to group and user group

                **FIT positive**   **PPV for AN no. (%)**     **OR**   **95% CI**   ***P-*value**[a](#t4-fn2){ref-type="fn"}
  ------------- ------------------ ------------------------ ---------- ------------ ------------------------------------------
  Non-users     365                184 (50.4)                1 (Ref.)                
  Users group   21                 10 (47.6)                   0.7     0.3--1.8     0.5
   OAC          13                 4 (30.8)                    0.4     0.1--1.3     0.14
   OAC+others   8                  6 (75)                      2.0     0.4--10.8    0.4

Abbreviations: AN=advanced neoplasia; CI=confidence interval; OAC=oral anticoagulants; OR=odds ratio; Others=aspirin ⩽300 mg day^--1^ or clopidogrel; PPV= positive predictive value.

Compared with non-users and adjusted for age and sex.

[^1]: All investigators are listed in the Supplementary note.
